Flat urothelial carcinoma in situ of the bladder with glandular differentiation

Antonio Lopez-Beltran, Rafael E. Jimenez, Rodolfo Montironi, Carlo Patriarca, Ana Blanca, Carmen L. Menendez, Ferran Algaba, Liang Cheng

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We present the clinicopathologic and immunonohistochemical features of 25 cases of flat urothelial carcinoma in situ with glandular differentiation. Previously, cases on this category have been reported as in situ adenocarcinoma (a term not currently preferred). Fourteen of 25 cases had concurrent conventional urothelial carcinoma in situ. Five of the cases were primary carcinoma in situ with glandular differentiation; twenty cases of secondary carcinoma in situ with glandular differentiation were associated with urothelial carcinoma alone (n = 11) or with glandular differentiation (n = 7), discohesive (n = 1) or micropapillary carcinoma (n = 1). The individual tumor cells were columnar. The architectural pattern of the carcinoma in situ with glandular differentiation consisted of 1 or more papillary, flat or cribriform glandular patterns. Univariate statistical analysis showed no survival differences between urothelial carcinoma in situ with glandular differentiation and conventional urothelial carcinoma in situ (log-rank 0.810; P =.368). Carcinoma in situ with glandular differentiation showed high ki-67 index and p53 accumulation, high nuclear and cytoplasmic p16 expression and diffuse PTEN expression, a phenotype that also characterized concurrent conventional carcinoma in situ. MUC5A, MUC2, CK20, and c-erbB2 were positive in all 25 cases of urothelial carcinoma in situ with glandular differentiation, and CDX-2 was present in 19 cases; MUC1, CK7, or 34βE12 was focally present in 21, 19, and 18 cases, respectively. MUC1core was negative in all cases. We concluded that urothelial carcinoma in situ with glandular differentiation is a variant of carcinoma in situ that follows the natural history of conventional urothelial carcinoma in situ. The immunophenotype suggests urothelial origin with the expression of MUC5A and CDX2 as signature for glandular differentiation.

Original languageEnglish
Pages (from-to)1653-1659
Number of pages7
JournalHuman Pathology
Volume42
Issue number11
DOIs
StatePublished - Nov 2011

Fingerprint

Carcinoma in Situ
Urinary Bladder
Carcinoma

Keywords

  • Adenocarcinoma in situ
  • Carcinoma in situ
  • CIS
  • Glandular differentiation
  • MUC5A

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Lopez-Beltran, A., Jimenez, R. E., Montironi, R., Patriarca, C., Blanca, A., Menendez, C. L., ... Cheng, L. (2011). Flat urothelial carcinoma in situ of the bladder with glandular differentiation. Human Pathology, 42(11), 1653-1659. https://doi.org/10.1016/j.humpath.2010.12.024

Flat urothelial carcinoma in situ of the bladder with glandular differentiation. / Lopez-Beltran, Antonio; Jimenez, Rafael E.; Montironi, Rodolfo; Patriarca, Carlo; Blanca, Ana; Menendez, Carmen L.; Algaba, Ferran; Cheng, Liang.

In: Human Pathology, Vol. 42, No. 11, 11.2011, p. 1653-1659.

Research output: Contribution to journalArticle

Lopez-Beltran, A, Jimenez, RE, Montironi, R, Patriarca, C, Blanca, A, Menendez, CL, Algaba, F & Cheng, L 2011, 'Flat urothelial carcinoma in situ of the bladder with glandular differentiation', Human Pathology, vol. 42, no. 11, pp. 1653-1659. https://doi.org/10.1016/j.humpath.2010.12.024
Lopez-Beltran A, Jimenez RE, Montironi R, Patriarca C, Blanca A, Menendez CL et al. Flat urothelial carcinoma in situ of the bladder with glandular differentiation. Human Pathology. 2011 Nov;42(11):1653-1659. https://doi.org/10.1016/j.humpath.2010.12.024
Lopez-Beltran, Antonio ; Jimenez, Rafael E. ; Montironi, Rodolfo ; Patriarca, Carlo ; Blanca, Ana ; Menendez, Carmen L. ; Algaba, Ferran ; Cheng, Liang. / Flat urothelial carcinoma in situ of the bladder with glandular differentiation. In: Human Pathology. 2011 ; Vol. 42, No. 11. pp. 1653-1659.
@article{0c981cbda32548828ff9fdee9a72b1d9,
title = "Flat urothelial carcinoma in situ of the bladder with glandular differentiation",
abstract = "We present the clinicopathologic and immunonohistochemical features of 25 cases of flat urothelial carcinoma in situ with glandular differentiation. Previously, cases on this category have been reported as in situ adenocarcinoma (a term not currently preferred). Fourteen of 25 cases had concurrent conventional urothelial carcinoma in situ. Five of the cases were primary carcinoma in situ with glandular differentiation; twenty cases of secondary carcinoma in situ with glandular differentiation were associated with urothelial carcinoma alone (n = 11) or with glandular differentiation (n = 7), discohesive (n = 1) or micropapillary carcinoma (n = 1). The individual tumor cells were columnar. The architectural pattern of the carcinoma in situ with glandular differentiation consisted of 1 or more papillary, flat or cribriform glandular patterns. Univariate statistical analysis showed no survival differences between urothelial carcinoma in situ with glandular differentiation and conventional urothelial carcinoma in situ (log-rank 0.810; P =.368). Carcinoma in situ with glandular differentiation showed high ki-67 index and p53 accumulation, high nuclear and cytoplasmic p16 expression and diffuse PTEN expression, a phenotype that also characterized concurrent conventional carcinoma in situ. MUC5A, MUC2, CK20, and c-erbB2 were positive in all 25 cases of urothelial carcinoma in situ with glandular differentiation, and CDX-2 was present in 19 cases; MUC1, CK7, or 34βE12 was focally present in 21, 19, and 18 cases, respectively. MUC1core was negative in all cases. We concluded that urothelial carcinoma in situ with glandular differentiation is a variant of carcinoma in situ that follows the natural history of conventional urothelial carcinoma in situ. The immunophenotype suggests urothelial origin with the expression of MUC5A and CDX2 as signature for glandular differentiation.",
keywords = "Adenocarcinoma in situ, Carcinoma in situ, CIS, Glandular differentiation, MUC5A",
author = "Antonio Lopez-Beltran and Jimenez, {Rafael E.} and Rodolfo Montironi and Carlo Patriarca and Ana Blanca and Menendez, {Carmen L.} and Ferran Algaba and Liang Cheng",
year = "2011",
month = "11",
doi = "10.1016/j.humpath.2010.12.024",
language = "English",
volume = "42",
pages = "1653--1659",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "11",

}

TY - JOUR

T1 - Flat urothelial carcinoma in situ of the bladder with glandular differentiation

AU - Lopez-Beltran, Antonio

AU - Jimenez, Rafael E.

AU - Montironi, Rodolfo

AU - Patriarca, Carlo

AU - Blanca, Ana

AU - Menendez, Carmen L.

AU - Algaba, Ferran

AU - Cheng, Liang

PY - 2011/11

Y1 - 2011/11

N2 - We present the clinicopathologic and immunonohistochemical features of 25 cases of flat urothelial carcinoma in situ with glandular differentiation. Previously, cases on this category have been reported as in situ adenocarcinoma (a term not currently preferred). Fourteen of 25 cases had concurrent conventional urothelial carcinoma in situ. Five of the cases were primary carcinoma in situ with glandular differentiation; twenty cases of secondary carcinoma in situ with glandular differentiation were associated with urothelial carcinoma alone (n = 11) or with glandular differentiation (n = 7), discohesive (n = 1) or micropapillary carcinoma (n = 1). The individual tumor cells were columnar. The architectural pattern of the carcinoma in situ with glandular differentiation consisted of 1 or more papillary, flat or cribriform glandular patterns. Univariate statistical analysis showed no survival differences between urothelial carcinoma in situ with glandular differentiation and conventional urothelial carcinoma in situ (log-rank 0.810; P =.368). Carcinoma in situ with glandular differentiation showed high ki-67 index and p53 accumulation, high nuclear and cytoplasmic p16 expression and diffuse PTEN expression, a phenotype that also characterized concurrent conventional carcinoma in situ. MUC5A, MUC2, CK20, and c-erbB2 were positive in all 25 cases of urothelial carcinoma in situ with glandular differentiation, and CDX-2 was present in 19 cases; MUC1, CK7, or 34βE12 was focally present in 21, 19, and 18 cases, respectively. MUC1core was negative in all cases. We concluded that urothelial carcinoma in situ with glandular differentiation is a variant of carcinoma in situ that follows the natural history of conventional urothelial carcinoma in situ. The immunophenotype suggests urothelial origin with the expression of MUC5A and CDX2 as signature for glandular differentiation.

AB - We present the clinicopathologic and immunonohistochemical features of 25 cases of flat urothelial carcinoma in situ with glandular differentiation. Previously, cases on this category have been reported as in situ adenocarcinoma (a term not currently preferred). Fourteen of 25 cases had concurrent conventional urothelial carcinoma in situ. Five of the cases were primary carcinoma in situ with glandular differentiation; twenty cases of secondary carcinoma in situ with glandular differentiation were associated with urothelial carcinoma alone (n = 11) or with glandular differentiation (n = 7), discohesive (n = 1) or micropapillary carcinoma (n = 1). The individual tumor cells were columnar. The architectural pattern of the carcinoma in situ with glandular differentiation consisted of 1 or more papillary, flat or cribriform glandular patterns. Univariate statistical analysis showed no survival differences between urothelial carcinoma in situ with glandular differentiation and conventional urothelial carcinoma in situ (log-rank 0.810; P =.368). Carcinoma in situ with glandular differentiation showed high ki-67 index and p53 accumulation, high nuclear and cytoplasmic p16 expression and diffuse PTEN expression, a phenotype that also characterized concurrent conventional carcinoma in situ. MUC5A, MUC2, CK20, and c-erbB2 were positive in all 25 cases of urothelial carcinoma in situ with glandular differentiation, and CDX-2 was present in 19 cases; MUC1, CK7, or 34βE12 was focally present in 21, 19, and 18 cases, respectively. MUC1core was negative in all cases. We concluded that urothelial carcinoma in situ with glandular differentiation is a variant of carcinoma in situ that follows the natural history of conventional urothelial carcinoma in situ. The immunophenotype suggests urothelial origin with the expression of MUC5A and CDX2 as signature for glandular differentiation.

KW - Adenocarcinoma in situ

KW - Carcinoma in situ

KW - CIS

KW - Glandular differentiation

KW - MUC5A

UR - http://www.scopus.com/inward/record.url?scp=80054695845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054695845&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2010.12.024

DO - 10.1016/j.humpath.2010.12.024

M3 - Article

VL - 42

SP - 1653

EP - 1659

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 11

ER -